Advances in the relationship between thyroid stimulating hormone receptor and papillary thyroid carcinoma

doi:10.3877/cma.j.issn.1674-0793.2020.06.018

Abstract

Abstract:

Papillary thyroid carcinoma (PTC) is the most common thyroid cancer. It has been found that the development of PTC is closely related to thyroid stimulating hormone receptor (TSHR). TSHR mutation is not uncommon in PTC, which is related to lymph node metastasis, and it can also induce PTC. PTC has a high risk of TSHR promoter methylation, which may contribute to the pathological diagnosis and stage of PTC. The level of TSHR transcription in peripheral blood of PTC increases significantly before operation, recurrence and metastasis, while it decreases significantly after operation, which is helpful for preoperative diagnosis and postoperative follow-up of PTC, and it also related to PTC lymph node metastasis. TSHR protein has abnormal expression level and distribution in PTC, which may also be related to the distant metastasis of PTC. In addition, other genes such as BRAF V600E mutation, lncRNA-PVT1 and miRNA-106a may regulate the expression of TSHR in PTC.

Key words: Thyroid stimulating hormone receptor, Papillary thyroid carcinoma, Gene mutation, Methylation, Diagnosis

Chuanxin Yang, Dongzhu Da, Kunru Zhang, Jun Liu. Advances in the relationship between thyroid stimulating hormone receptor and papillary thyroid carcinoma[J]. Chinese Archives of General Surgery(Electronic Edition), 2020, 14(06): 467-470.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2020.06.018

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2020/V14/I06/467

References 25

[1]	Adhami M, Michail P, Rao A, et al. Anti-thyroid antibodies and TSH as potential markers of thyroid carcinoma and aggressive behavior in patients with indeterminate fine-needle aspiration cytology[J]. World J Surg, 2020, 44(2): 363-370.
[2]	Fang Y, Sun F, Zhang RJ, et al. Mutation screening of the TSHR gene in 220 Chinese patients with congenital hypothyroidism[J]. Clin Chim Acta, 2019, 497: 147-152.
[3]	Stephen JK, Chen KM, Merritt J, et al. Methylation markers differentiate thyroid cancer from benign nodules[J]. J Endocrinol Invest, 2018, 41(2): 163-170.
[4]	Aliyev A, Gupta M, Nasr C, et al. Circulating thyroid-stimulating hormone rececptor messenger RNA as a marker of tumor aggressiveness in patients with papillary throid microcarcinnoma[J]. Endocr Pract, 2015, 21(7): 777-781.
[5]	Liu TR, Su X, Qiu WS, et al. Thyroid-stimulating hormone receptor affects metastasis and prognosis in papillary thyroid carcinoma[J]. Eur Rev Med Pharmacol Sci, 2016, 20(17): 3582-3591.
[6]	Rousseau-Merck MF, Misrahi M, Loosfelt H, et al. Assignment of the human thyroid stimulating hormone receptor (TSHR) gene to chromosome 14q31[J]. Genomics, 1990, 8(2): 233-236.
[7]	Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma[J]. Cell, 2014, 159(3): 676-690.
[8]	Kocsis-Deák B, Árvai K, Balla B, et al. Targeted mutational profiling and a powerful risk score as additional tools for the diagnosis of papillary thyroid cancer[J]. Pathol Oncol Res, 2020, 26(1): 101-108.
[9]	Neumann S, Krause G, Chey S, et al. A free carboxylate oxygen in the side chain of position 674 in transmembrane domain 7 is necessary for TSH receptor activation[J]. Mol Endocrinol, 2001, 15(8): 1294-1305.
[10]	Jaeschke H, Undeutsch H, Patyra K, et al. Hyperthyroidism and papillary thyroid carcinoma in thyrotropin receptor D633H mutant mice[J]. Thyroid, 2018, 28(10): 1372-1386.
[11]	Su X, Lin LW, Weng JL, et al. TSHR rs2288496 associated with thyroid hormone and predict the occurrence of lymph node metastasis of papillary thyroid cancer[J]. Cancer Biomark, 2019, 26(4): 461-470.
[12]	Kartal K, Onder S, Kosemehmetoglu K, et al. Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material[J]. BMC Cancer, 2015, 15(1): 824.
[13]	张晨, 霍倩, 李翠珍, 等. 促甲状腺激素受体基因甲基化与甲状腺乳头状癌关联的Meta分析[J]. 中国全科医学, 2013, 16(28): 3371-3375.
[14]	Mohammadi-asl J, Larijani B, Khorgami Z, et al. Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARβ2 genes in papillary thyroid carcinoma[J]. Med Oncol, 2011, 28(4): 1123-1128.
[15]	Chia SY, Milas M, Reddy SK, et al. Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer[J]. J Clin Endocrinol Metab, 2007, 92(2): 468-475.
[16]	Liu R, Hao S, Zhang H, et al. Correlation of thyroid stimulating hormone receptor mRNA expression levels in peripheral blood with undesirable clinicopathological features in papillary thyroid carcinoma patients[J]. Oncotarget, 2017, 8(43): 74129-74138.
[17]	Aliyev A, Soundararajan S, Bucak E, et al. The utility of peripheral thyrotropin receptor mRNA in the management of differentiated thyroid cancer[J]. Surgery, 2015, 158(4): 1089-1093.
[18]	Wang ZF, Liu QJ, Liao SQ, et al. Expression and correlation of sodium/iodide symporter and thyroid stimulating hormone receptor in human thyroid carcinoma[J]. Tumori, 2011, 97(4): 540-546.
[19]	刘春萍, 楚慧敏, 明洁, 等. 促甲状腺激素受体及碘钠泵在人甲状腺癌中的表达及临床意义[J]. 解剖学报, 2008, 39(5): 756-759.
[20]	郝少龙, 马纪红, 刘新承, 等. 甲状腺乳头状癌组织TSHR表达与BRAFV600E基因突变的关系研究[J/CD]. 中华普外科手术学杂志(电子版), 2018, 12(6): 468-471.
[21]	Kim YH, Choi YW, Han JH, et al. TSH signaling overcomes B-RafV600E-induced senescence in papillary thyroid carcino-genesis through regulation of DUSP6[J]. Neoplasia, 2014, 16(12): 1107-1120.
[22]	Kleiman DA, Buitrago D, Crowley MJ, et al. Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing[J]. J Surg Res, 2013, 182(1): 85-93.
[23]	Zhou C, Li J, Wang Y, et al. Association of BRAF gene and TSHR with cervical lymph node metastasis of papillary thyroid microcarcinoma[J]. Oncol Lett, 2019, 17(1): 183-194.
[24]	Zhou Q, Chen J, Feng J, et al. Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR)[J]. Tumour Biol, 2016, 37(3): 3105-3113.
[25]	Shen CT, Qiu ZL, Song HJ, et al. miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(-) symporter in thyroid cancer by regulating MAPK signaling pathway[J]. J Exp Clin Cancer Res, 2016, 35(1): 101.

Please choose a citation manager

Content to export